KLF15 Agonist Phase I

KLF15 Agonist Phase I

KLF15 Agonist Phase I

The KLF15 Agonist Phase I project targets albuminuria in chronic kidney disease, offering a potentially safer and more effective alternative to glucocorticoid therapy for conditions like FSGS and MCD. With promising efficacy and reduced toxicity, this novel approach is progressing towards patent licensing and IND roadmap development, aiming for accelerated FDA approval.

Problem

Albuminuria (Proteinuria) is a major determinant of chronic kidney disease progression.
FSGS/MCD (Focal Segmental Glomerulosclerosis/Minimal Change Disease) - rare diseases, but large market opportunity due to unmet medical need of Chronic Kidney Disease (CKD), FSGS primary treatment is glucocorticoid therapy.
Glucocorticoid usage can be associated with serious long term side effects.

Solution

KLF15 is a novel target for therapy in proteinuric kidney diseases. KLF15 Small molecule agonists demonstrate improved efficacy and reduced systemic toxicity to dexamethasone.
Substantial potential for indication expansion Proteinuria (surrogate endpoint for primary glomerular diseases accelerated FDA approval).

Progress

In discussion to license composition-of-matter patent (COM) recently-approved patent on KLF15 agonists from the Veteran Affairs. Performing science due diligence. Mapping out IND roadmap.

Want to learn more?

Join our active discord community to connect with researchers, patients, and supporters working together to advance the future of kidney health.

Explore more project proposals

FDA Cleared Patented Facial RPM AI

FDA Cleared Patented Facial RPM AI

Smartphone-based Facial remote patient management (RPM) AI, providing an affordable alternative to costly monitoring devices. FDA-cleared and patent-protected, it targets conditions like hypertension and CKD. Ready for deployment, it aims to revolutionize personalized medicine, beginning with mental health.

View project

CareToken: Unlocking the Potential of Healthcare Assets

CareYield: Unlocking the Potential of Healthcare Assets

CareYield leverages blockchain, AI, and community to tokenize healthcare assets, creating a liquid marketplace. It aims to accelerate innovation, improve outcomes, and reduce costs, targeting crypto investors while maintaining regulatory compliance.

View project

Decentralized Independent Physician Association (DeIPA)

Decentralized Independent Physician Association (DeIPA)

KidneyDAO's DeIPA is a revolutionary model that demonstrates the potential of CareYield's platform. By leveraging blockchain technology, artificial intelligence, and tokenization, DeIPA has addressed the limitations of traditional IPAs, unlocking new opportunities for growth, efficiency, and patient care.

View project

Dialysis AI Humanoid Robotic Staffing

Dialysis AI Humanoid Robotic Staffing

The Dialysis AI Humanoid Robotic Staffing project tackles the nephrology professional shortage through an AI-driven staffing platform, patient-provider matching app, and humanoid robots. With a revenue-generating platform already operational and patent-pending AI and robotic solutions in development, it aims to optimize dialysis care delivery and staffing efficiency.

View project

Intel MedPatch AI

Intel MedPatch AI

Intel MedPatch AI tackles medication non-compliance through automated lab testing and microneedle drug delivery. This system aims to reduce healthcare costs and medication errors, especially for elderly and rural patients. With patents for CKD and CHF, an obesity management grant, and potential Epogen partnership, it's progressing towards wider application.

View project

Are you working on a project to advance kidney health?
We offer research funding and translational support for
promising and innovative projects in kidney health.

Learn more about how we can help accelerate your research.

Apply for research funding

Learn more about the KNEY token

Everything you need to know about the governance token that powers our community.